Medprin Regenerative Medical Technologies Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100004NB8
CNY
63.80
2.05 (3.32%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a growth in Net Profit of 39.89%, the company declared Outstanding results in Sep 25

  • The company has declared positive results for the last 6 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at CNY 136.76 MM
  • INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
  • ROCE(HY) Highest at 14.41%
2

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 1,086 Million (Small Cap)

stock-summary
P/E

52.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.82%

stock-summary
Debt Equity

-0.34

stock-summary
Return on Equity

13.55%

stock-summary
Price to Book

1.45

Revenue and Profits:
Net Sales:
91 Million
(Quarterly Results - Sep 2025)
Net Profit:
29 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.28%
0%
-8.28%
6 Months
-13.43%
0%
-13.43%
1 Year
31.09%
0%
31.09%
2 Years
99.31%
0%
99.31%
3 Years
41.37%
0%
41.37%
4 Years
42.09%
0%
42.09%
5 Years
0%
0%
0.0%

Medprin Regenerative Medical Technologies Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
20.91%
EBIT Growth (5y)
59.77%
EBIT to Interest (avg)
35.56
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.38
Tax Ratio
14.29%
Dividend Payout Ratio
50.34%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.56%
ROE (avg)
8.17%

Valuation key factors

Factor
Value
P/E Ratio
52
Industry P/E
Price to Book Value
6.85
EV to EBIT
50.64
EV to EBITDA
38.71
EV to Capital Employed
9.60
EV to Sales
15.19
PEG Ratio
1.00
Dividend Yield
0.18%
ROCE (Latest)
18.96%
ROE (Latest)
13.12%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 32.80% vs 14.64% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 40.20% vs 51.11% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "91.50",
          "val2": "68.90",
          "chgp": "32.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "29.40",
          "val2": "27.50",
          "chgp": "6.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "28.60",
          "val2": "20.40",
          "chgp": "40.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "321.10%",
          "val2": "297.90%",
          "chgp": "2.32%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.66% vs 17.42% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 92.91% vs 14.57% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "275.70",
          "val2": "228.50",
          "chgp": "20.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "102.50",
          "val2": "68.60",
          "chgp": "49.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "2.40",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "0.10",
          "chgp": "-400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "78.90",
          "val2": "40.90",
          "chgp": "92.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "270.60%",
          "val2": "183.90%",
          "chgp": "8.67%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary

Sep'25
Sep'24
Change(%)
Net Sales
91.50
68.90
32.80%
Operating Profit (PBDIT) excl Other Income
29.40
27.50
6.91%
Interest
0.00
0.00
Exceptional Items
0.30
0.00
Consolidate Net Profit
28.60
20.40
40.20%
Operating Profit Margin (Excl OI)
321.10%
297.90%
2.32%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2025 is 32.80% vs 14.64% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 40.20% vs 51.11% in Sep 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
275.70
228.50
20.66%
Operating Profit (PBDIT) excl Other Income
102.50
68.60
49.42%
Interest
1.20
2.40
-50.00%
Exceptional Items
-0.30
0.10
-400.00%
Consolidate Net Profit
78.90
40.90
92.91%
Operating Profit Margin (Excl OI)
270.60%
183.90%
8.67%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 20.66% vs 17.42% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 92.91% vs 14.57% in Dec 2023

stock-summaryCompany CV
About Medprin Regenerative Medical Technologies Co., Ltd. stock-summary
stock-summary
Medprin Regenerative Medical Technologies Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available